Determination of Drug Sensitivity Subgroups in Endometrial Cancer Based on Renin Angiotensin System

Turk, Seyhan

doi:10.14744/etd.2022.45220

Determination of Drug Sensitivity Subgroups in Endometrial Cancer Based on Renin Angiotensin System

Seyhan TÜRK (Department of Biochemistry, Hacettepe University Faculty of Pharmacy, Ankara, Türkiye)

Erciyes Medical Journal

7 0

Yıl: 2022 Cilt: 44 Sayı: 5 Sayfa Aralığı: 495 - 500 Metin Dili: İngilizce DOI: 10.14744/etd.2022.45220 İndeks Tarihi: 02-10-2022

Determination of Drug Sensitivity Subgroups in Endometrial Cancer Based on Renin Angiotensin System

Öz:

Objective: The renin angiotensin system (RAS) is a prognostic molecular target for a large cancer group and plays an essential role in cancer biology. This critical system affects tumor growth and spread, both directly and indirectly, including endometrial cancer (EC). RAS activation has been strongly associated with the expression of angiogenesis, metastasis, and pro-angiogenic factors. The aim of this study was to identify EC subgroups according to variations in RAS genes and evaluate the prediction of chemotherapy resistance. Materials and Methods: Hierarchical clustering, variance, t-test, fold change, false discovery rate calculation, and geneset enrichment analyses were performed using microarray and drug sensitivity data obtained from the Genomics of Drug Sensitivity in Cancer Project database and the European Molecular Biology Laboratory-European Bioinformatics Institute ArrayExpress (accession no: E-MTAB-783). Results: Subgroups of endometrial cancer cell lines were determined based on the RAS gene family. These subgroups were associated with 2 critical chemotherapeutic agents: vinblastine and epothilone B. Important gene sets were identified in the subgroups. Conclusion: Pharmacological effects of RAS genes may differ in EC cells, depending on the pathological behavior of genomic subtypes. The results of this study showed that RAS genes were potential biomarkers for drug sensitivity and prognosis of endometrial cancer. RAS and NOTCH/autophagosome pathways may be related in EC. If the data of this study are confirmed by in vitro experiments and clinical samples, RAS genes would seem to be robust prognostic biomarkers for vinblastine and epothilone B.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Baltagiannis EG, Kyrochristos ID, Ziogas DE, Goussia A, Mitsis M, Roukos DH. From personalized to precision cancer medicine. Per Med 2020; 17(4): 245–50.
2. Chiong JR, Aronow WS, Khan IA, Nair CK, Vijayaraghavan K, Dart RA, et al. Secondary hypertension: current diagnosis and treatment. Int J Cardiol 2008; 124(1): 6–21.
3. Bader M. Tissue renin-angiotensin-aldosterone systems: Targets for pharmacological therapy. Annu Rev Pharmacol Toxicol 2010; 50: 439–65.
4. Haznedaroğlu IC, Tuncer S, Gürsoy M. A local renin-angiotensin system in the bone marrow. Med Hypotheses 1996; 46(6): 507–10.
5. Abali H, Güllü IH, Engin H, Haznedaroğlu IC, Erman M, Tekuzman G. Old antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Med Hypotheses 2002; 59(3): 344–8.
6. Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis 2008; 29(9): 1675–84.
7. George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer 2010; 10(11): 745–59.
8. Delforce SJ, Lumbers ER, Corbisier de Meaultsart C, Wang Y, Proietto A, et al. Expression of renin-angiotensin system (RAS) components in endometrial cancer. Endocr Connect 2017; 6(1): 9–19.
9. Turk S, Turk C, Akbar MW, Kucukkaraduman B, Isbilen M, Demirkol Canli S, et al. Renin angiotensin system genes are biomarkers for personalized treatment of acute myeloid leukemia with Doxorubicin as well as etoposide. PLoS One 2020; 15(11): e0242497.
10. Khoshghamat N, Jafari N, Toloue-Pouya V, Azami S, Mirnourbakhsh SH, Khazaei M, et al. The therapeutic potential of renin-angiotensin system inhibitors in the treatment of pancreatic cancer. Life Sci 2021; 270: 119118.
11. Lindemann K, Vatten LJ, Ellstrøm-Engh M, Eskild A. Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study. Br J Cancer 2008; 98(9): 1582–5.
12. Hamilton CA, Pothuri B, Arend RC, Backes FJ, Gehrig PA, Soliman PT, et al. Endometrial cancer: A society of gynecologic oncology evidence- based review and recommendations, part II. Gynecol Oncol 2021; 160(3): 827–34.
13. Li XF, Ahmed A. Compartmentalization and cyclic variation of immunoreactivity of renin and angiotensin converting enzyme in human endometrium throughout the menstrual cycle. Hum Reprod 1997; 12(12): 2804–9.
14. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012; 483(7391): 570–5.
15. Simon RM. Design and analysis of DNA microarray investigations. 1st ed. London: Springer; 2011.
16. Wang J, Nishiyama A, Matsuyama M, Wang Z, Yuan Y. The (pro)renin receptor: a novel biomarker and potential therapeutic target for various cancers. Cell Commun Signal 2020; 18(1): 39.
17. Li SY, Song Z, Yan YP, Li B, Song MJ, Liu YF, et al. Aldosterone from endometrial glands is benefit for human decidualization. Cell Death Dis 2020; 11(8): 679.
18. Piastowska-Ciesielska AW, Płuciennik E, Wójcik-Krowiranda K, Bieńkiewicz A, Bednarek A, Ochędalski T. Analysis of the expression of angiotensin II type 1 receptor and VEGF in endometrial adenocarcinoma with different clinicopathological characteristics. Tumour Biol 2012; 33(3): 767–74.
19. Ino K, Shibata K, Kajiyama H, Yamamoto E, Nagasaka T, Nawa A, et al. Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival. Br J Cancer 2006; 94(4): 552–60.
20. Kinoshita J, Fushida S, Harada S, Yagi Y, Fujita H, Kinami S, et al. Local angiotensin II-generation in human gastric cancer: correlation with tumor progression through the activation of ERK1/2, NF-kappaB and survivin. Int J Oncol 2009; 34(6): 1573–82.
21. Röcken C, Lendeckel U, Dierkes J, Westphal S, Carl-McGrath S, Peters B, et al. The number of lymph node metastases in gastric cancer correlates with the angiotensin I-converting enzyme gene insertion/ deletion polymorphism. Clin Cancer Res 2005; 11(7): 2526–30.
22. Uemura H, Hasumi H, Ishiguro H, Teranishi J, Miyoshi Y, Kubota Y. Renin-angiotensin system is an important factor in hormone refractory prostate cancer. Prostate 2006; 66(8): 822–30.
23. Rhodes DR, Ateeq B, Cao Q, Tomlins SA, Mehra R, Laxman B, et al. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci U S A 2009; 106(25): 10284–9.
24. Rodriguez-Vita J, Tetzlaff F, Fischer A. Notch controls endothelial cells. Oncoscience 2017; 4(5-6): 45–6.
25. Polychronidou G, Kotoula V, Manousou K, Kostopoulos I, Karayannopoulou G, Vrettou E, et al. Mismatch repair deficiency and aberrations in the Notch and Hedgehog pathways are of prognostic value in patients with endometrial cancer. PLoS One 2018; 13(12): e0208221.
26. Das G, Shravage BV, Baehrecke EH. Regulation and function of autophagy during cell survival and cell death. Cold Spring Harb Perspect Biol 2012; 4(6): a008813.
27. Deng L, Feng J, Broaddus RR. The novel estrogen-induced gene EIG121 regulates autophagy and promotes cell survival under stress. Cell Death Dis 2010; 1(4): e32.
28. Liu S, Li X. Autophagy inhibition enhances sensitivity of endometrial carcinoma cells to paclitaxel. Int J Oncol 2015; 46(6): 2399–408.

APA	Turk S (2022). Determination of Drug Sensitivity Subgroups in Endometrial Cancer Based on Renin Angiotensin System. , 495 - 500. 10.14744/etd.2022.45220
Chicago	Turk Seyhan Determination of Drug Sensitivity Subgroups in Endometrial Cancer Based on Renin Angiotensin System. (2022): 495 - 500. 10.14744/etd.2022.45220
MLA	Turk Seyhan Determination of Drug Sensitivity Subgroups in Endometrial Cancer Based on Renin Angiotensin System. , 2022, ss.495 - 500. 10.14744/etd.2022.45220
AMA	Turk S Determination of Drug Sensitivity Subgroups in Endometrial Cancer Based on Renin Angiotensin System. . 2022; 495 - 500. 10.14744/etd.2022.45220
Vancouver	Turk S Determination of Drug Sensitivity Subgroups in Endometrial Cancer Based on Renin Angiotensin System. . 2022; 495 - 500. 10.14744/etd.2022.45220
IEEE	Turk S "Determination of Drug Sensitivity Subgroups in Endometrial Cancer Based on Renin Angiotensin System." , ss.495 - 500, 2022. 10.14744/etd.2022.45220
ISNAD	Turk, Seyhan. "Determination of Drug Sensitivity Subgroups in Endometrial Cancer Based on Renin Angiotensin System". (2022), 495-500. https://doi.org/10.14744/etd.2022.45220

APA	Turk S (2022). Determination of Drug Sensitivity Subgroups in Endometrial Cancer Based on Renin Angiotensin System. Erciyes Medical Journal, 44(5), 495 - 500. 10.14744/etd.2022.45220
Chicago	Turk Seyhan Determination of Drug Sensitivity Subgroups in Endometrial Cancer Based on Renin Angiotensin System. Erciyes Medical Journal 44, no.5 (2022): 495 - 500. 10.14744/etd.2022.45220
MLA	Turk Seyhan Determination of Drug Sensitivity Subgroups in Endometrial Cancer Based on Renin Angiotensin System. Erciyes Medical Journal, vol.44, no.5, 2022, ss.495 - 500. 10.14744/etd.2022.45220
AMA	Turk S Determination of Drug Sensitivity Subgroups in Endometrial Cancer Based on Renin Angiotensin System. Erciyes Medical Journal. 2022; 44(5): 495 - 500. 10.14744/etd.2022.45220
Vancouver	Turk S Determination of Drug Sensitivity Subgroups in Endometrial Cancer Based on Renin Angiotensin System. Erciyes Medical Journal. 2022; 44(5): 495 - 500. 10.14744/etd.2022.45220
IEEE	Turk S "Determination of Drug Sensitivity Subgroups in Endometrial Cancer Based on Renin Angiotensin System." Erciyes Medical Journal, 44, ss.495 - 500, 2022. 10.14744/etd.2022.45220
ISNAD	Turk, Seyhan. "Determination of Drug Sensitivity Subgroups in Endometrial Cancer Based on Renin Angiotensin System". Erciyes Medical Journal 44/5 (2022), 495-500. https://doi.org/10.14744/etd.2022.45220